



Dr. Julian MÄRZ, Switzerland

Dr. iur., Dr. med. et Dr. sc. med. Julian W. März has studied law, medicine, and bioethics at the Universities of Zurich, Oxford, Munich, Regensburg, and Passau, and the Institut d'Études Politiques (IEP) de Paris. He holds a master's degree in economic law from the IEP de Paris (2016), a Ph.D. in Law (Dr. iur.) from the University of Passau (2020), a Ph.D. in Bioethics (Dr. sc. med.) from the University of Zurich (2023), and a Doctorate in Medicine (Dr. med.) from the University of Regensburg (2023). In addition, he holds the German State Diploma in Medicine (2023) and is licensed as physician in Switzerland. His university studies have been funded by full scholarships from the German National Academic Foundation (Studienstiftung des deutschen Volkes).

Before joining the University of Zurich as a research fellow in October 2022, he has worked for the Division of Health Economics at the German Cancer Research Center (DKFZ) in Heidelberg, where he also wrote his doctoral thesis in medicine. In parallel, he has worked as research affiliate in pharmaceutical law for the Centre for Law, Medicine, and Life Sciences of the University of Cambridge, and as lecturer in public health law at the IEP de Paris. Furthermore, he has worked as a trainee lawyer for the international law firms Cleary Gottlieb Steen & Hamilton LLP and Hogan Lovells LLP and as a trainee physician at the General Hospital of Luxembourg.

Julian is currently a research fellow at the Institute of Biomedical Ethics and History of Medicine (IBME) at the Medical Faculty of the University of Zurich and an associated researcher at the Digital Society Initiative (DSI), the Competence Center Medicine – Ethics – Law Helvetiae (MERH), and the University Research Priority Program (URPP) Innovative Therapies in Rare Diseases (ITINERARE) of the University of Zurich. In addition, he is lecturing in the fields of biomedical innovation law, pharmaceutical law, and medical ethics at the University of Zurich, the Zurich University of Applied Sciences (ZHAW), and the Swiss Distance University of Applied Sciences (FFHS). In parallel, he advises the World Health Organization (WHO) on a number of topics in the area of digital and public health ethics. Since March 2023, he has been leading the curriculum development project “Integrating ethics and governance into the design of artificial intelligence technologies for health” of the WHO Digital Health and Innovation (DHI) and Health Ethics & Governance (HEG) Units.

Julian's main research interests lie in the areas of biomedical innovation law, research ethics, and pharmaceutical pricing, with a particular focus on gene and cell therapies, AI in pharmaceutical R&D, and innovative therapies for rare diseases.